(Q43595601)

25 November 2017

title

Good news about pulmonary hypertension (English)

1 reference

25 November 2017

Barberà J

1

1 reference

25 November 2017

language of work or name

Spanish

0 references

publication date

1 March 2001

1 reference

Archivos de Bronconeumologia

25 November 2017

published in

1 reference

25 November 2017

volume

37

1 reference

25 November 2017

issue

3

1 reference

25 November 2017

page(s)

105-107

1 reference

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Primary pulmonary hypertension. A national prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Severe pulmonary hypertensive diseases: a perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31–32

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Primary pulmonary hypertension: natural history and the importance of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Death in a patient with primary pulmonary hypertension after 20 mg of nifedipine.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Minimizing the inhaled dose of NO with breath-by-breath delivery of spikes of concentrated gas.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2801%2975030-2

7 January 2021

10.1016/S0300-2896(01)75030-2

Identifiers

DOI

1 reference

25 November 2017

1 reference